Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study.

ABSTRACT:

Objective

Binge eating disorder (BED) is the most common eating disorder, and yet only one pharmacotherapy (lisdexamfetamine), which has known abuse-potential, is FDA-approved. Topiramate is also commonly prescribed off-label for binge eating but has many contraindications. In contrast, the glucagon-like peptide-1 (GLP1) analog semaglutide has profound effects on central satiety signaling leading to reduced food intake, and has been approved for the treatment of obesity based on its efficacy and safety profile. Semaglutide would thus seem to be a potential candidate for the treatment of BED.

Methods

This open-label study examined the effects of semaglutide on Binge Eating Scale (BES) scores in individuals with BED. Patients were divided into three groups: those prescribed se

SUBMITTER: Richards J 

PROVIDER: S-EPMC10661993 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature